{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:59:24Z","timestamp":1790236764168,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007780","name":"Indian Institute of Science","doi-asserted-by":"publisher","award":["MoE-STARS\/STARS-2\/2023-0928"],"award-info":[{"award-number":["MoE-STARS\/STARS-2\/2023-0928"]}],"id":[{"id":"10.13039\/100007780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.bbapap.2026.141177","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:01:35Z","timestamp":1789722095000},"page":"141177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Indoleamine 2,3-dioxygenase 1 inhibitors: Molecular pharmacology, structural biology and medicinal chemistry with therapeutic perspectives for Huntington's disease"],"prefix":"10.1016","volume":"1875","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2772-364X","authenticated-orcid":false,"given":"Vishnu","family":"Malakar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9478-017X","authenticated-orcid":false,"given":"Chandi C.","family":"Malakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2019-0492","authenticated-orcid":false,"given":"Pratap Chand","family":"Mali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2162-9110","authenticated-orcid":false,"given":"Nitesh Kumar","family":"Poddar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbapap.2026.141177_bb0005","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3233\/JHD-180293","article-title":"Clinical management of neuropsychiatric symptoms of huntington disease: Expert-based consensus guidelines on agitation, anxiety, apathy, psychosis and sleep disorders","volume":"7","author":"Anderson","year":"2018","journal-title":"J. Huntingtons Dis."},{"key":"10.1016\/j.bbapap.2026.141177_bb0010","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2217\/nmt-2016-0008","article-title":"The global prevalence of Huntington\u2019s disease: a systematic review and discussion","volume":"6","author":"Baig","year":"2016","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.bbapap.2026.141177_bb0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00004850-200403000-00001","article-title":"Huntington\u2019s disease: Present treatments and future therapeutic modalities","volume":"19","author":"Bonelli","year":"2004","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.bbapap.2026.141177_bb0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mds.23953","article-title":"Pharmacologic approaches to the treatment of Huntington\u2019s disease","volume":"27","author":"Venuto","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbapap.2026.141177_bb0025","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3988\/jcn.2006.2.4.213","article-title":"Therapeutic Strategies in Huntington\u2019s Disease","volume":"2","author":"Kanazawa","year":"2006","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.bbapap.2026.141177_bb0030","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11064-025-04509-5","article-title":"Targeting IDO1 in Huntington\u2019s disease: network pharmacology and preclinical evidence from Coffea arabica","volume":"50","author":"Malakar","year":"2025","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.bbapap.2026.141177_bb0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/14728222.2019.1549231","article-title":"Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington\u2019s disease","volume":"23","author":"Boros","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bbapap.2026.141177_bb0040","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrn3257","article-title":"Kynurenines in the mammalian brain: when physiology meets pathology","volume":"13","author":"Schwarcz","year":"2012","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bbapap.2026.141177_bb0045","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/jnc.14907","article-title":"Does kynurenic acid act on nicotinic receptors? An assessment of the evidence","volume":"152","author":"Stone","year":"2020","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbapap.2026.141177_bb0050","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/j.1742-4658.2012.08485.x","article-title":"Quinolinic acid, the inescapable neurotoxin","volume":"279","author":"Guillemin","year":"2012","journal-title":"FEBS J."},{"key":"10.1016\/j.bbapap.2026.141177_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-026-47343-7","article-title":"Computational investigation of biochanin a targeting DEPTOR in Alzheimer\u2019s disease with in vitro cellular validation of neuroprotective activity","author":"Malakar","year":"2026","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbapap.2026.141177_bb0060","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s10571-026-01702-0","article-title":"Narrative review \u201cdual frontiers in neurodegeneration: pharmacological synergies and divergences in parkinson\u2019s disease and type 2 diabetes mellitus,\u201d","volume":"46","author":"Sharallah","year":"2026","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.bbapap.2026.141177_bb0065","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.gene.2007.04.010","article-title":"Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice","volume":"396","author":"Ball","year":"2007","journal-title":"Gene"},{"key":"10.1016\/j.bbapap.2026.141177_bb0070","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00262-012-1265-x","article-title":"Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation","volume":"61","author":"Qian","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbapap.2026.141177_bb0075","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/intimm\/dxt073","article-title":"IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation","volume":"26","author":"Metz","year":"2014","journal-title":"Int. Immunol."},{"key":"10.1016\/j.bbapap.2026.141177_bb0080","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.neuropharm.2016.03.013","article-title":"Kynurenine pathway metabolites and enzymes involved in redox reactions","volume":"112","author":"Gonz\u00e1lez Esquivel","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbapap.2026.141177_bb0085","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1016\/S0021-9258(18)99420-2","article-title":"Tryptophan pyrrolase of rabbit intestine. D- and L-tryptophan-cleaving enzyme or enzymes","volume":"242","author":"Yamamoto","year":"1967","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbapap.2026.141177_bb0090","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1111\/febs.16086","article-title":"Indoleamine 2,3\u2010dioxygenase 1 (IDO1): an up\u2010to\u2010date overview of an eclectic immunoregulatory enzyme","volume":"289","author":"Pallotta","year":"2022","journal-title":"FEBS J."},{"key":"10.1016\/j.bbapap.2026.141177_bb0095","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41467-017-01725-8","article-title":"Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1","volume":"8","author":"Lewis-Ballester","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbapap.2026.141177_bb0100","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2005.03.013","article-title":"GCN2 Kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase","volume":"22","author":"Munn","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.bbapap.2026.141177_bb0105","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.4049\/jimmunol.0900986","article-title":"IDO activates regulatory T cells and blocks their conversion into Th17-Like T cells","volume":"183","author":"Baban","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbapap.2026.141177_bb0110","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0952-7915(97)80079-9","article-title":"Inhibitory receptors, ITIM sequences and phosphatases","volume":"9","author":"Unkeless","year":"1997","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.bbapap.2026.141177_bb0115","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/ni.2077","article-title":"Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells","volume":"12","author":"Pallotta","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbapap.2026.141177_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2026.111507","article-title":"Network pharmacology and computational-based approaches to activate NRF2 pathway via KEAP1 and GSK-3\u03b2 inhibition: exploring the possible molecular insights of mangiferin for Alzheimer\u2019s","volume":"204","author":"Malakar","year":"2026","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.bbapap.2026.141177_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202403078","article-title":"Exploring the multi\u2010target effects of Valeriana officinalis in alzheimer\u2019s disease: a network pharmacology approach","volume":"10","author":"Malakar","year":"2025","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bbapap.2026.141177_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202403082","article-title":"Deciphering potent protein tyrosine phosphatase\u20101B inhibitors through in silico molecular docking, MMGBSA, and molecular dynamics","volume":"10","author":"Malakar","year":"2025","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bbapap.2026.141177_bb0135","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.neuropharm.2015.10.036","article-title":"Allosteric modulation of metabotropic glutamate receptor 4 activates IDO1-dependent, immunoregulatory signaling in dendritic cells","volume":"102","author":"Volpi","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbapap.2026.141177_bb0140","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.biocel.2008.01.005","article-title":"Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway","volume":"41","author":"Ball","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.bbapap.2026.141177_bb0145","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1038\/cddis.2012.74","article-title":"Perk-dependent repression of miR-106b-25 cluster is required for ER stress-induced apoptosis","volume":"3","author":"Gupta","year":"2012","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbapap.2026.141177_bb0150","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1073\/pnas.85.15.5733","article-title":"Differential loss of striatal projection neurons in Huntington disease","volume":"85","author":"Reiner","year":"1988","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbapap.2026.141177_bb0155","doi-asserted-by":"crossref","first-page":"7082","DOI":"10.1158\/0008-5472.CAN-07-1872","article-title":"Novel tryptophan catabolic enzyme IDO2 Is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound <scp>d<\/scp> -1-methyl-tryptophan","volume":"67","author":"Metz","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2026.141177_bb0160","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/jnc.12350","article-title":"Age\u2010dependent alterations of the kynurenine pathway in the <scp>YAC<\/scp> 128 mouse model of Huntington disease","volume":"127","author":"Mazarei","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbapap.2026.141177_bb0165","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.molmed.2013.02.007","article-title":"Tryptophan metabolism: entering the field of aging and age-related pathologies","volume":"19","author":"van der Goot","year":"2013","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bbapap.2026.141177_bb0170","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.cbpb.2009.02.002","article-title":"Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases","volume":"153","author":"Yuasa","year":"2009","journal-title":"Comp. Biochem. Physiol. B Biochem. Mol. Biol."},{"key":"10.1016\/j.bbapap.2026.141177_bb0175","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1471-4159.2005.03070.x","article-title":"Tryptophan metabolism and oxidative stress in patients with Huntington\u2019s disease","volume":"93","author":"Stoy","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbapap.2026.141177_bb0180","doi-asserted-by":"crossref","first-page":"17247","DOI":"10.1074\/jbc.271.29.17247","article-title":"Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-\u03b3-inducible expression of human indoleamine 2,3-dioxygenase gene","volume":"271","author":"Chon","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"1994","key":"10.1016\/j.bbapap.2026.141177_bb0185","first-page":"1415","article-title":"Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins","volume":"264","author":"Darnell","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.bbapap.2026.141177_bb0190","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbapap.2026.141177_bb0195","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1073\/pnas.1117736109","article-title":"Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase","volume":"109","author":"Ravishankar","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbapap.2026.141177_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.102.034439","article-title":"Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities","volume":"303","author":"Schwarcz","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbapap.2026.141177_bb0205","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2174\/187152707783399229","article-title":"Kynurenine pathway and disease: an overview","volume":"6","author":"Santamaria","year":"2007","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.bbapap.2026.141177_bb0210","doi-asserted-by":"crossref","DOI":"10.4137\/IJTR.S8158","article-title":"Quinolinic acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms","volume":"5","author":"La Cruz","year":"2012","journal-title":"Intern. J. Tryptoph. Res."},{"key":"10.1016\/j.bbapap.2026.141177_bb0215","series-title":"3-hydroxykynurenine is a ROS-Inducing Cytotoxic Tryptophan Metabolite that Disrupts the TCA Cycle","author":"Buchanan","year":"2023"},{"key":"10.1016\/j.bbapap.2026.141177_bb0220","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1073\/pnas.0508996103","article-title":"Crystal structure of human indoleamine 2,3-dioxygenase: Catalytic mechanism of O2 incorporation by a heme-containing dioxygenase","volume":"103","author":"Sugimoto","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbapap.2026.141177_bb0225","doi-asserted-by":"crossref","first-page":"17690","DOI":"10.1021\/acs.jmedchem.1c01665","article-title":"Structure and plasticity of indoleamine 2,3-dioxygenase 1 (IDO1)","volume":"64","author":"R\u00f6hrig","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbapap.2026.141177_bb0230","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1021\/acs.jmedchem.5b01390","article-title":"Important hydrogen bond networks in indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor design revealed by crystal structures of imidazoleisoindole derivatives with IDO1","volume":"59","author":"Peng","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbapap.2026.141177_bb0235","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1107\/S2059798320013510","article-title":"Influence of the presence of the heme cofactor on the JK-loop structure in indoleamine 2,3-dioxygenase 1","volume":"76","author":"Mirgaux","year":"2020","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"10.1016\/j.bbapap.2026.141177_bb0240","doi-asserted-by":"crossref","first-page":"15788","DOI":"10.1074\/jbc.M200457200","article-title":"The heme environment of recombinant human indoleamine 2,3-dioxygenase","volume":"277","author":"Terentis","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbapap.2026.141177_bb0245","doi-asserted-by":"crossref","first-page":"9421","DOI":"10.1021\/acs.jmedchem.5b00326","article-title":"Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors","volume":"58","author":"R\u00f6hrig","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbapap.2026.141177_bb0250","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/0003-9861(91)90142-6","article-title":"1-methyl-dl-tryptophan, \u03b2-(3-benzofuranyl)-dl-alanine (the oxygen analog of tryptophan), and \u03b2-[3-benzo(b)thienyl]-dl-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase","volume":"291","author":"Cady","year":"1991","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbapap.2026.141177_bb0255","doi-asserted-by":"crossref","first-page":"16046","DOI":"10.1021\/ja067211+","article-title":"Exiguamine A, an indoleamine-2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua","volume":"128","author":"Brastianos","year":"2006","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bbapap.2026.141177_bb0260","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1039\/c3ob42258e","article-title":"Benzofuranquinones as inhibitors of indoleamine 2,3-dioxygenase (IDO). Synthesis and biological evaluation","volume":"12","author":"Carvalho","year":"2014","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.bbapap.2026.141177_bb0265","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/ja.2013.134","article-title":"Inhibition of indoleamine 2,3-dioxygenase by thielavin derivatives from a soil fungus, Coniochaeta sp. 10F058","volume":"67","author":"Jang","year":"2014","journal-title":"J. Antibiot. (Tokyo)"},{"key":"10.1016\/j.bbapap.2026.141177_bb0270","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/ja.2011.141","article-title":"Benzomalvin E, an indoleamine 2,3-dioxygenase inhibitor isolated from Penicillium sp","volume":"65","author":"Jang","year":"2012","journal-title":"FN070315, J. Antibiot. (Tokyo)."},{"key":"10.1016\/j.bbapap.2026.141177_bb0275","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1021\/acsmedchemlett.6b00391","article-title":"INCB24360 (Epacadostat), a highly potent and selective indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor for immuno-oncology","volume":"8","author":"Yue","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bbapap.2026.141177_bb0280","doi-asserted-by":"crossref","DOI":"10.1007\/s12094-026-04526-y","article-title":"Targeting protein\u2013protein interactions in the BCL-2 family: opportunities for precision oncology","author":"Malakar","year":"2026","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.bbapap.2026.141177_bb0285","doi-asserted-by":"crossref","DOI":"10.1007\/s11101-026-10240-y","article-title":"Withanolides as molecular inhibitors in oral squamous cell carcinoma: unveiling anticancer mechanisms and therapeutic targets","author":"Malakar","year":"2026","journal-title":"Phytochem. Rev."},{"key":"10.1016\/j.bbapap.2026.141177_bb0290","doi-asserted-by":"crossref","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","article-title":"Discovery of IDO1 inhibitors: from bench to bedside","volume":"77","author":"Prendergast","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2026.141177_bb0295","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1021\/acs.jmedchem.7b00974","article-title":"Discovery of a novel and selective indoleamine 2,3-dioxygenase (IDO-1) inhibitor 3-(5-Fluoro-1 H -indol-3-yl)pyrrolidine-2,5-dione (EOS200271\/PF-06840003) and its characterization as a potential clinical candidate","volume":"60","author":"Crosignani","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbapap.2026.141177_bb0300","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/jcph.855","article-title":"Population pharmacokinetic and pharmacodynamic modeling of epacadostat in patients with advanced solid malignancies","volume":"57","author":"Shi","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bbapap.2026.141177_bb0305","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1158\/1078-0432.CCR-16-2272","article-title":"First-in-human phase I Study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies","volume":"23","author":"Beatty","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbapap.2026.141177_bb0310","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ygyno.2017.07.005","article-title":"A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)\u2013only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer","volume":"146","author":"Kristeleit","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bbapap.2026.141177_bb0315","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/cncr.34512","article-title":"Phase 1\/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors","volume":"129","author":"Naing","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.bbapap.2026.141177_bb0320","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1158\/1078-0432.CCR-22-3911","article-title":"A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma","volume":"29","author":"Kelly","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbapap.2026.141177_bb0325","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40425-019-0562-8","article-title":"Phase 1\/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma","volume":"7","author":"Gibney","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbapap.2026.141177_bb0330","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/oncolo\/oyac174","article-title":"Epacadostat plus pembrolizumab and chemotherapy for advanced solid tumors: results from the phase I\/II ECHO-207\/KEYNOTE-723 study","volume":"27","author":"Powderly","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.bbapap.2026.141177_bb0335","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1200\/JCO.2022.40.16_suppl.2058","article-title":"Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295","volume":"40","author":"Campian","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbapap.2026.141177_bb0340","doi-asserted-by":"crossref","first-page":"9511","DOI":"10.1200\/JCO.2018.36.15_suppl.9511","article-title":"Epacadostat plus nivolumab for advanced melanoma: updated phase 2 results of the ECHO-204 study","volume":"36","author":"Daud","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbapap.2026.141177_bb0345","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1158\/1078-0432.CCR-18-2740","article-title":"Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (Atezolizumab) in advanced solid tumors","volume":"25","author":"Jung","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbapap.2026.141177_bb0350","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1200\/JCO.2018.36.15_suppl.3040","article-title":"First-in-human study of KHK2455, a long-acting, potent and selective indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, in combination with mogamulizumab (Moga), an anti-CCR4 monoclonal antibody, in patients (pts) with advanced solid tumors","volume":"36","author":"Yap","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbapap.2026.141177_bb0355","first-page":"OF1","article-title":"Phase 1\/2 Study of the indoleamine 2,3-dioxygenase 1 inhibitor linrodostat mesylate combined with nivolumab or nivolumab and ipilimumab in advanced solid tumors or hematologic malignancies","author":"Luke","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbapap.2026.141177_bb0360","doi-asserted-by":"crossref","first-page":"P250","DOI":"10.1186\/2051-1426-2-S3-P250","article-title":"A Phase I study of NLG919 for adult patients with recurrent advanced solid tumors","volume":"2","author":"Nayak","year":"2014","journal-title":"J. Immunother. Cancer"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570963926000543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570963926000543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:10:14Z","timestamp":1790233814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570963926000543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2027,1]]}},"alternative-id":["S1570963926000543"],"URL":"https:\/\/doi.org\/10.1016\/j.bbapap.2026.141177","relation":{},"ISSN":["1570-9639"],"issn-type":[{"value":"1570-9639","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Indoleamine 2,3-dioxygenase 1 inhibitors: Molecular pharmacology, structural biology and medicinal chemistry with therapeutic perspectives for Huntington's disease","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbapap.2026.141177","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"141177"}}